Galapagos NV (GLPG)
27.13
+1.91
(+7.57%)
USD |
NASDAQ |
Nov 22, 16:00
27.12
-0.02
(-0.06%)
After-Hours: 20:00
Galapagos Revenue (Quarterly): 65.82M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 65.82M |
| June 30, 2024 | 83.85M |
| March 31, 2024 | 67.81M |
| December 31, 2023 | 64.55M |
| September 30, 2023 | 66.59M |
| June 30, 2023 | 65.48M |
| March 31, 2023 | 62.91M |
| December 31, 2022 | -172.72M |
| September 30, 2022 | 137.21M |
| June 30, 2022 | 146.58M |
| March 31, 2022 | 153.00M |
| December 31, 2021 | -95.47M |
| September 30, 2021 | 75.69M |
| June 30, 2021 | 168.45M |
| March 31, 2021 | 137.24M |
| December 31, 2020 | 186.15M |
| September 30, 2020 | 149.12M |
| June 30, 2020 | 109.68M |
| March 31, 2020 | 104.64M |
| December 31, 2019 | 120.90M |
| September 30, 2019 | 704.88M |
| Date | Value |
|---|---|
| June 30, 2019 | 65.99M |
| March 31, 2019 | 37.54M |
| December 31, 2018 | 109.77M |
| September 30, 2018 | 110.32M |
| June 30, 2018 | 59.31M |
| March 31, 2018 | 46.57M |
| December 31, 2017 | 46.18M |
| September 30, 2017 | 31.68M |
| June 30, 2017 | 29.63M |
| March 31, 2017 | 36.21M |
| December 31, 2016 | 85.78M |
| September 30, 2016 | 12.52M |
| June 30, 2016 | 32.40M |
| March 31, 2016 | 11.16M |
| December 31, 2015 | 7.868M |
| September 30, 2015 | 6.340M |
| June 30, 2015 | 13.12M |
| March 31, 2015 | 16.70M |
| December 31, 2014 | 25.29M |
| September 30, 2014 | 18.11M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-172.72M
Minimum
Dec 2022
186.15M
Maximum
Dec 2020
84.87M
Average
94.24M
Median
Revenue (Quarterly) Benchmarks
| UCB SA | -- |
| Mithra Pharmaceuticals SA | -- |
| Nyxoah SA | 1.392M |
| Celyad Oncology SA | -- |
| MDxHealth SA | 23.32M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -55.46M |
| Total Expenses (Quarterly) | 125.55M |
| EPS Diluted (Quarterly) | -0.8469 |
| Enterprise Value | -1.941B |
| Gross Profit Margin (Quarterly) | 99.97% |
| Profit Margin (Quarterly) | -84.26% |
| Earnings Yield | 12.41% |
| Normalized Earnings Yield | -3.745 |